$CYTH
Cyclo Therapeutics, Inc.

2021 Q1 Form 10-Q Financial Statement

#000143774921012317 Filed on May 14, 2021

View on sec.gov

Income Statement

Concept 2021 Q1 2020 Q1
Revenue $358.1K $325.7K
YoY Change 9.95% 47.51%
Cost Of Revenue $36.26K $30.00K
YoY Change 20.87% 45.99%
Gross Profit $321.9K $300.0K
YoY Change 7.29% 49.79%
Gross Profit Margin 89.87% 92.1%
Selling, General & Admin $1.097M $880.0K
YoY Change 24.71% 15.79%
% of Gross Profit 340.97% 293.33%
Research & Development $3.258M $2.060M
YoY Change 58.19% 53.39%
% of Gross Profit 1012.25% 686.54%
Depreciation & Amortization $3.550K $3.118K
YoY Change 13.86% 110.11%
% of Gross Profit 1.1% 1.04%
Operating Expenses $3.258M $2.060M
YoY Change 58.19% 53.39%
Operating Profit -$4.037M -$2.642M
YoY Change 52.81% 38.49%
Interest Expense $660.00 $10.00K
YoY Change -93.4%
% of Operating Profit
Other Income/Expense, Net $661.00
YoY Change
Pretax Income -$4.037M -$2.634M
YoY Change 53.25% 38.33%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$4.037M -$2.634M
YoY Change 53.25% 38.33%
Net Earnings / Revenue -1127.13% -808.63%
Basic Earnings Per Share -$0.76
Diluted Earnings Per Share -$756.8K -$2.174M
COMMON SHARES
Basic Shares Outstanding 5.334M 121.7M
Diluted Shares Outstanding

Balance Sheet

Concept 2021 Q1 2020 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $15.51M $930.0K
YoY Change 1567.39% -16.96%
Cash & Equivalents $15.51M $933.5K
Short-Term Investments
Other Short-Term Assets $2.036M $730.0K
YoY Change 178.96% 1456.47%
Inventory $257.8K $228.8K
Prepaid Expenses
Receivables $171.9K $168.8K
Other Receivables $48.31K $40.00K
Total Short-Term Assets $18.02M $2.097M
YoY Change 759.27% 24.28%
LONG-TERM ASSETS
Property, Plant & Equipment $50.36K $61.06K
YoY Change -17.52% 231.62%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $120.2K $188.8K
YoY Change -36.35% -13.25%
TOTAL ASSETS
Total Short-Term Assets $18.02M $2.097M
Total Long-Term Assets $120.2K $188.8K
Total Assets $18.14M $2.286M
YoY Change 693.56% 19.99%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.628M $3.940M
YoY Change -7.91% 50.38%
Accrued Expenses $18.33K $20.00K
YoY Change -8.35% 100.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $60.14K
YoY Change
Total Short-Term Liabilities $3.707M $3.952M
YoY Change -6.21% 49.9%
LONG-TERM LIABILITIES
Long-Term Debt $98.38K $0.00
YoY Change
Other Long-Term Liabilities $14.56K $30.00K
YoY Change -51.47% -40.0%
Total Long-Term Liabilities $112.9K $30.00K
YoY Change 276.47% -40.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $3.707M $3.952M
Total Long-Term Liabilities $112.9K $30.00K
Total Liabilities $3.820M $3.980M
YoY Change -4.03% 47.96%
SHAREHOLDERS EQUITY
Retained Earnings -$38.10M -$27.75M
YoY Change 37.27% 42.39%
Common Stock $635.00 $12.16K
YoY Change -94.78% 33.94%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $14.32M -$1.698M
YoY Change
Total Liabilities & Shareholders Equity $18.14M $2.286M
YoY Change 693.56% 19.99%

Cashflow Statement

Concept 2021 Q1 2020 Q1
OPERATING ACTIVITIES
Net Income -$4.037M -$2.634M
YoY Change 53.25% 38.33%
Depreciation, Depletion And Amortization $3.550K $3.118K
YoY Change 13.86% 110.11%
Cash From Operating Activities -$4.927M -$1.809M
YoY Change 172.31% 47.67%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $50.63K
YoY Change -100.0% 3723.79%
Acquisitions
YoY Change
Other Investing Activities $3.330K $10.00K
YoY Change -66.7% 0.0%
Cash From Investing Activities $3.332K -$41.01K
YoY Change -108.12% -619.67%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $7.584M
YoY Change
NET CHANGE
Cash From Operating Activities -$4.927M -1.809M
Cash From Investing Activities $3.332K -41.01K
Cash From Financing Activities $7.584M
Net Change In Cash $2.661M -1.850M
YoY Change -243.8% 67.86%
FREE CASH FLOW
Cash From Operating Activities -$4.927M -$1.809M
Capital Expenditures $0.00 $50.63K
Free Cash Flow -$4.927M -$1.860M
YoY Change 164.9% 51.63%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q1 ctdh Cost Of Goods And Services Sold Excluding Direct And Indirect Overhead And Handling Costs
CostOfGoodsAndServicesSoldExcludingDirectAndIndirectOverheadAndHandlingCosts
34596
CY2020Q1 ctdh Cost Of Goods And Services Sold Excluding Direct And Indirect Overhead And Handling Costs
CostOfGoodsAndServicesSoldExcludingDirectAndIndirectOverheadAndHandlingCosts
26433
CY2021Q1 ctdh Prepaid Expenses Current Excluding Prepaid Insurance
PrepaidExpensesCurrentExcludingPrepaidInsurance
1816633
CY2021Q1 ctdh Freight And Shipping
FreightAndShipping
1513
CY2020Q1 ctdh Freight And Shipping
FreightAndShipping
1863
CY2021Q1 ctdh Increase Decrease Prepaid Clinical Expenses
IncreaseDecreasePrepaidClinicalExpenses
1088681
CY2020Q1 ctdh Increase Decrease Prepaid Clinical Expenses
IncreaseDecreasePrepaidClinicalExpenses
-59096
CY2016Q1 ctdh Mortgage Loans On Real Estate Monthly Payment
MortgageLoansOnRealEstateMonthlyPayment
3653
CY2021Q1 ctdh Number Of Major Customers
NumberOfMajorCustomers
3
CY2020Q1 ctdh Number Of Major Customers
NumberOfMajorCustomers
3
CY2020Q4 ctdh Prepaid Expenses Current Excluding Prepaid Insurance
PrepaidExpensesCurrentExcludingPrepaidInsurance
727952
CY2021Q1 ctdh Repairs And Maintenance
RepairsAndMaintenance
1666
CY2020Q1 ctdh Repairs And Maintenance
RepairsAndMaintenance
1802
CY2021Q1 ctdh Sharebased Compensation Employees
SharebasedCompensationEmployees
CY2020Q1 ctdh Sharebased Compensation Employees
SharebasedCompensationEmployees
2470
CY2021Q1 ctdh Sharebased Compensation Nonemployees
SharebasedCompensationNonemployees
CY2020Q1 ctdh Sharebased Compensation Nonemployees
SharebasedCompensationNonemployees
4750
CY2021Q1 ctdh Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
7584092
CY2021Q1 dei Security12b Title
Security12bTitle
Common Stock, par value $.0001 per share
CY2021Q1 dei Trading Symbol
TradingSymbol
ctdh
CY2016Q1 srt Mortgage Loans On Real Estate Face Amount Of Mortgages
MortgageLoansOnRealEstateFaceAmountOfMortgages
265000
CY2016Q1 srt Mortgage Loans On Real Estate Interest Rate
MortgageLoansOnRealEstateInterestRate
0.0425
CY2021Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
3628293
CY2020Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
3541041
CY2021Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
171864
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
71017
CY2021Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
52419383
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
44513841
CY2021Q1 us-gaap Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
-890204
CY2020Q1 us-gaap Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
824742
CY2021Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
0
CY2020Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7220
CY2021Q1 us-gaap Assets
Assets
18141269
CY2020Q4 us-gaap Assets
Assets
14187964
CY2021Q1 us-gaap Assets Current
AssetsCurrent
18021105
CY2020Q4 us-gaap Assets Current
AssetsCurrent
14050237
CY2021Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
15506718
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12846113
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
12846113
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
2783719
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
15506718
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
933457
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
2660605
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-1850262
CY2021Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
10000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
10000000
CY2021Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
6357596
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
4770761
CY2021Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
6357596
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
4770761
CY2021Q1 us-gaap Common Stock Value
CommonStockValue
635
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
477
CY2021Q1 us-gaap Costs And Expenses
CostsAndExpenses
4395409
CY2020Q1 us-gaap Costs And Expenses
CostsAndExpenses
2967774
CY2021Q1 us-gaap Depreciation
Depreciation
3550
CY2020Q1 us-gaap Depreciation
Depreciation
3118
CY2021Q1 us-gaap Depreciation Nonproduction
DepreciationNonproduction
3550
CY2020Q1 us-gaap Depreciation Nonproduction
DepreciationNonproduction
3118
CY2021Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.76
CY2020Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.17
CY2021Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-4036615
CY2020Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-2633992
CY2021Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
CY2020Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
CY2021Q1 us-gaap Income Taxes Paid
IncomeTaxesPaid
CY2020Q1 us-gaap Income Taxes Paid
IncomeTaxesPaid
CY2021Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
358560
CY2020Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
803630
CY2021Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
100847
CY2020Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
25394
CY2021Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
19925
CY2020Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-13859
CY2021Q1 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
CY2020Q1 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
9615
CY2021Q1 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-117
CY2020Q1 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-226
CY2021Q1 us-gaap Increase Decrease In Prepaid Insurance
IncreaseDecreaseInPrepaidInsurance
93278
CY2020Q1 us-gaap Increase Decrease In Prepaid Insurance
IncreaseDecreaseInPrepaidInsurance
37013
CY2021Q1 us-gaap Interest Paid Net
InterestPaidNet
CY2020Q1 us-gaap Interest Paid Net
InterestPaidNet
CY2021Q1 us-gaap Inventory Net
InventoryNet
257834
CY2020Q4 us-gaap Inventory Net
InventoryNet
237909
CY2021Q1 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
52922
CY2021Q1 us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
661
CY2020Q1 us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
8048
CY2021Q1 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
50300
CY2020Q1 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
CY2021Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
18141269
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
14187964
CY2021Q1 us-gaap Liabilities Current
LiabilitiesCurrent
3706760
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3672553
CY2021Q1 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
112942
CY2020Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
62929
CY2021Q1 us-gaap Long Term Accounts Notes And Loans Receivable Net Noncurrent
LongTermAccountsNotesAndLoansReceivableNetNoncurrent
38942
CY2020Q4 us-gaap Long Term Accounts Notes And Loans Receivable Net Noncurrent
LongTermAccountsNotesAndLoansReceivableNetNoncurrent
49806
CY2021Q1 us-gaap Long Term Notes Payable
LongTermNotesPayable
98382
CY2020Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
44495
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
7584092
CY2020Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
CY2021Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
3332
CY2020Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-41012
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4926819
CY2020Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1809250
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-4036615
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-2633992
CY2021Q1 us-gaap Noninterest Expense Directors Fees
NoninterestExpenseDirectorsFees
CY2020Q1 us-gaap Other Selling General And Administrative Expense
OtherSellingGeneralAndAdministrativeExpense
178362
CY2021Q1 us-gaap Payments For Proceeds From Loans Receivable
PaymentsForProceedsFromLoansReceivable
-3332
CY2020Q1 us-gaap Payments For Proceeds From Loans Receivable
PaymentsForProceedsFromLoansReceivable
-9615
CY2021Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
CY2020Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
50627
CY2021Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2020Q1 us-gaap Noninterest Expense Directors Fees
NoninterestExpenseDirectorsFees
7349
CY2021Q1 us-gaap Notes And Loans Receivable Net Current
NotesAndLoansReceivableNetCurrent
48304
CY2020Q4 us-gaap Notes And Loans Receivable Net Current
NotesAndLoansReceivableNetCurrent
40772
CY2021Q1 us-gaap Notes Payable Current
NotesPayableCurrent
60142
CY2020Q4 us-gaap Notes Payable Current
NotesPayableCurrent
114029
CY2021Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-4037276
CY2020Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-2642040
CY2021Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
18325
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
17483
CY2021Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
14560
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
18434
CY2021Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
30862
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
34011
CY2021Q1 us-gaap Other Selling General And Administrative Expense
OtherSellingGeneralAndAdministrativeExpense
313774
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2021Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q1 us-gaap Prepaid Insurance
PrepaidInsurance
219752
CY2020Q4 us-gaap Prepaid Insurance
PrepaidInsurance
126474
CY2020Q3 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
2831114
CY2016Q1 us-gaap Proceeds From Sale Of Property Held For Sale
ProceedsFromSaleOfPropertyHeldForSale
10000
CY2021Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
7584092
CY2020Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
CY2021Q1 us-gaap Professional Fees
ProfessionalFees
222871
CY2020Q1 us-gaap Professional Fees
ProfessionalFees
219536
CY2021Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
50360
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
53910
CY2020Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2059606
CY2021Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3258115
CY2021Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-38098451
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-34061836
CY2021Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
358133
CY2020Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
325734
CY2021Q1 us-gaap Salaries And Wages
SalariesAndWages
559324
CY2020Q1 us-gaap Salaries And Wages
SalariesAndWages
469705
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
14321567
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
10452482
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
935982
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
-1698010
CY2021Q1 us-gaap Use Of Estimates
UseOfEstimates
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(q) USE OF ESTIMATES&#x2013;&#x2013;The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions, including regarding contingencies, that affect the amounts reported in the consolidated financial statements and accompanying notes. The Company's most significant estimate relates to inventory obsolescence. Although management bases its estimates on historical experience and assumptions that are believed to be reasonable under the circumstances, actual results could significantly differ from these estimates.</div></div></div></div></div></div></div>
CY2021Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
5333806
CY2020Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1215650

Files In Submission

Name View Source Status
0001437749-21-012317-index-headers.html Edgar Link pending
0001437749-21-012317-index.html Edgar Link pending
0001437749-21-012317.txt Edgar Link pending
0001437749-21-012317-xbrl.zip Edgar Link pending
ctdh-20210331.xml Edgar Link completed
ctdh-20210331.xsd Edgar Link pending
ctdh-20210331_cal.xml Edgar Link unprocessable
ctdh-20210331_def.xml Edgar Link unprocessable
ctdh-20210331_lab.xml Edgar Link unprocessable
ctdh-20210331_pre.xml Edgar Link unprocessable
ctdh20210331_10q.htm Edgar Link pending
ex_247871.htm Edgar Link pending
ex_247872.htm Edgar Link pending
ex_247873.htm Edgar Link pending
ex_247874.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending